Skip to main content

HCV Progress in Therapy with Novel Sialomimetic-chimeric inhibitors

Objective

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV), which affects liver and is mainly transmitted by blood-to-blood contact. Infection is often asymptomatic, but when chronicized it causes liver inflammation (chronic hepatitis). This condition can progress to fibrosis, cirrhosis and cancer. Socio-economical quality of life is seriously affected by several aspects including domestic environment and workplace. Besides any ethical issue, the impact on the European and national health systems has a major relevance due to high costs of pharmacological treatments.
At present, no vaccine against HCV is available. Standard therapy is currently based on double or triple combination (peginterferon, ribavirin and protease inhibitor), but it is ineffective to reduce symptoms in about 40% of cases, while clearance from viremia is not achievable.
The market for HCV drugs is set to rapidly grow in the forthcoming years as new and more effective therapies will be available. Despite many scientific publications have envisaged during the most recent years the design and the study of new compounds targeting the glycans of the glycoproteins of the HCV envelope (gp120), no such kind of compounds have been described until now.
Recent patent publications (WO2008/090151and WO2011/064303) have described innovative HCV inhibitors targeting such glycoproteins of HCV envelope. Some of those compounds have been already tested in typical in vitro assays eliciting a remarkable inhibitory activity on HCV. It remains to assess their effectiveness by implementing additional work packages. The current comprehensive proposal has been designed to develop the scientific and technological bases to assess most of the findings required to enter into clinical studies in humans with new HCV inhibiting compounds.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-SME-2012
See other projects for this call

Funding Scheme

BSG-SME - Research for SMEs

Coordinator

UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
Address
Duomo 6
13100 Vercelli
Italy
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 72 500
Administrative Contact
Francesco Cellerino (Dr.)

Participants (7)

THERAPICON
Italy
EU contribution
€ 443 000
Address
Via Malachia Marchesi De Taddei 21
20146 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Paolo Alberto Veronesi (Prof.)
CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH
Austria
EU contribution
€ 485 000
Address
Rudolfsplatz 2 1 8
1010 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mario Pinza (Dr.)
3S PHARMACOLOGICAL CONSULTATION & RES.SRL
Romania
EU contribution
€ 482 500
Address
Strada Sabinelor 52 Sectorul 5
050853 Bucuresti
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Loredana Georgiana Manolache (Dr.)
INSTITUTULUL NATIONAL DE CERCETARE-DEZVOLTARE CHIMICO-FARMACEUTICA
Romania
EU contribution
€ 13 000
Address
Calea Vitan 112
031299 Bucuresti
Activity type
Research Organisations
Administrative Contact
Iuksel Rasit (Dr.)
PHARMA SERV INTERNATIONAL SRL
Romania
EU contribution
€ 13 000
Address
Strada Sabinelor 52 Sectorul 5
050853 Bucuresti
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Luigi Silvestro (Dr.)
Aurigon Life Science GmbH
Germany
EU contribution
€ 13 000
Address
Bahnhofstrasse 9 - 15
D-82327 Tutzing
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gundel Hager (Dr.)
DUKE CHEM SA
Spain
EU contribution
€ 13 000
Address
Avinguda Mare De Deu De 99
08799 Olerdola
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Joan Amor (Mr.)